Fundraising Fox
/Companies
Sign in

Thymmune

Cambridge, US · 2 known investors

Find your way into Thymmune

Sign up to see every warm intro you have to Thymmune

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Thymmune team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Thymmune Therapeutics develops a machine learning-driven thymic cell engineering platform that mass-produces iPSC-derived thymic cells to restore immune function affected by aging and disease. The company is building a pipeline of off-the-shelf cell therapies for immunodeficiencies, transplant-related, and autoimmune disorders.

AI & Machine LearningBiotechLongevity

Founders & leadership

SWStan Wang
Stan WangMD, PhDStan Wang holds an MD from Columbia University (via the NIH Medical Scientist Training Program) and a PhD in stem cell biology and regenerative medicine from the University of Cambridge (as a Gates Scholar and NIH-Cambridge Scholar). He was a postdoctoral fellow with George Church at Harvard Medical School and served as Founding Chief Scientific Officer at Cellino Biotech before founding Thymmune Therapeutics, which develops iPSC-derived thymic cell therapies for immunodeficiencies and related disorders.
BLBing Lim
Bing LimMD, PhDBing Lim is an MD/PhD physician-scientist with 27 years of research experience at Harvard Medical School and the Genome Institute of Singapore, where his lab developed methods for pluripotent stem cell differentiation and identified markers and therapeutic targets in tumor-initiating cells. He previously held leadership roles in cell therapy and drug discovery at Sana Biotechnology (Senior Vice President) and Merck (Associate Vice President), where he led efforts in stem cell manipulation and translational development, as well as target identification and validation.
MJManish Jain
Manish JainManish Jain is a senior operations and manufacturing executive with 20+ years in biotech and biopharma, with expertise in CMC development, process engineering, regulatory strategy, and scaling cell and protein therapies from early stage through commercial production.

Investors · 2

NYBC Ventureslisted by NYBC VenturesNew York

How we know: funding news · Not right? Tell us

Funding

SEC filings, press & company announcements

$7M disclosed across 1 round · 2023

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Thymmune Raises $7M in Seed Financingfinsmes.com · Mar 2023Thymmune Secures $7M in Seed Financing to Develop Thymus Cell Therapy Platform for Immune System Renewal — Thymmune Therapeuticsthymmune.com · Mar 2023

Frequently asked questions

What does Thymmune do?
Thymmune Therapeutics develops a machine learning-driven thymic cell engineering platform that mass-produces iPSC-derived thymic cells to restore immune function affected by aging and disease. The company is building a pipeline of off-the-shelf cell therapies for immunodeficiencies, transplant-related, and autoimmune disorders.
Who founded Thymmune?
Thymmune was founded by Stan Wang, Bing Lim.
Who are Thymmune's investors?
Thymmune's investors include Pillar VC, NYBC Ventures.
How much funding has Thymmune raised?
Thymmune has disclosed $7M raised across 1 round.
Where is Thymmune headquartered?
Thymmune is headquartered in Cambridge, US.